Neumora Therapeutics, Common Stock Fundamentals
| NMRA Stock | 1.16 0.03 2.52% |
Neumora Therapeutics, Common fundamentals help investors to digest information that contributes to Neumora Therapeutics,'s financial success or failures. It also enables traders to predict the movement of Neumora Stock. The fundamental analysis module provides a way to measure Neumora Therapeutics,'s intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Neumora Therapeutics, stock.
At present, Neumora Therapeutics,'s Depreciation And Amortization is projected to increase significantly based on the last few years of reporting. The current year's Total Other Income Expense Net is expected to grow to about 20.8 M, whereas EBIT is forecasted to decline to (177.8 M).
Neumora | Select Account or Indicator |
Neumora Therapeutics, Common Company Return On Equity Analysis
Neumora Therapeutics,'s Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Neumora Therapeutics, Return On Equity | -0.64 |
Most of Neumora Therapeutics,'s fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Neumora Therapeutics, Common is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Neumora Total Stockholder Equity
Total Stockholder Equity |
|
At present, Neumora Therapeutics,'s Total Stockholder Equity is projected to increase significantly based on the last few years of reporting.
Based on the latest financial disclosure, Neumora Therapeutics, Common has a Return On Equity of -0.6448. This is 97.31% lower than that of the Pharmaceuticals sector and 98.23% lower than that of the Health Care industry. The return on equity for all United States stocks is 108.0% higher than that of the company.
Neumora Therapeutics, Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Neumora Therapeutics,'s current stock value. Our valuation model uses many indicators to compare Neumora Therapeutics, value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Neumora Therapeutics, competition to find correlations between indicators driving Neumora Therapeutics,'s intrinsic value. More Info.Neumora Therapeutics, Common is considered to be number one stock in return on equity category among its peers. It also is considered to be number one stock in return on asset category among its peers . At present, Neumora Therapeutics,'s Return On Equity is projected to slightly decrease based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Neumora Therapeutics,'s earnings, one of the primary drivers of an investment's value.Neumora Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Neumora Therapeutics,'s direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Neumora Therapeutics, could also be used in its relative valuation, which is a method of valuing Neumora Therapeutics, by comparing valuation metrics of similar companies.Neumora Therapeutics, is currently under evaluation in return on equity category among its peers.
Neumora Fundamentals
| Return On Equity | -0.64 | ||||
| Return On Asset | -0.4 | ||||
| Current Valuation | (112.97 M) | ||||
| Shares Outstanding | 161.98 M | ||||
| Shares Owned By Insiders | 27.52 % | ||||
| Shares Owned By Institutions | 71.98 % | ||||
| Number Of Shares Shorted | 11.2 M | ||||
| Price To Book | 0.67 X | ||||
| EBITDA | (263.46 M) | ||||
| Net Income | (243.79 M) | ||||
| Total Debt | 1.85 M | ||||
| Book Value Per Share | 1.77 X | ||||
| Cash Flow From Operations | (182.94 M) | ||||
| Short Ratio | 7.25 X | ||||
| Earnings Per Share | (1.53) X | ||||
| Target Price | 7.04 | ||||
| Number Of Employees | 110 | ||||
| Market Capitalization | 192.76 M | ||||
| Total Asset | 316.97 M | ||||
| Retained Earnings | (947.22 M) | ||||
| Working Capital | 284.17 M | ||||
| Net Asset | 316.97 M |
About Neumora Therapeutics, Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Neumora Therapeutics, Common's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Neumora Therapeutics, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Neumora Therapeutics, Common based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 24.4 M | 15.8 M | |
| Cost Of Revenue | 601.2 K | 571.1 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Neumora Therapeutics, offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Neumora Therapeutics,'s financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Neumora Therapeutics, Common Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Neumora Therapeutics, Common Stock:Check out Neumora Therapeutics, Piotroski F Score and Neumora Therapeutics, Altman Z Score analysis. You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neumora Therapeutics,. If investors know Neumora will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neumora Therapeutics, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Neumora Therapeutics, is measured differently than its book value, which is the value of Neumora that is recorded on the company's balance sheet. Investors also form their own opinion of Neumora Therapeutics,'s value that differs from its market value or its book value, called intrinsic value, which is Neumora Therapeutics,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neumora Therapeutics,'s market value can be influenced by many factors that don't directly affect Neumora Therapeutics,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neumora Therapeutics,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Neumora Therapeutics, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neumora Therapeutics,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.